Format

Send to

Choose Destination
Curr Opin Cardiol. 2011 Sep;26(5):420-3. doi: 10.1097/HCO.0b013e3283499ef1.

Combination therapy for dyslipidemia.

Author information

1
Department of Medicine, University of Ottawa, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada. msharma@Ottawahospital.on.ca

Abstract

PURPOSE OF REVIEW:

Residual cardiovascular risk remains in individuals treated with statins and combination therapies may reduce this risk further.

RECENT FINDINGS:

Most previous trials of combination therapies have shown a favorable effect on lipid profiles without clinical superiority over statin monotherapy. Trial design has been hampered by short duration and comparison with a low dose statin. The Study of Heart and Renal Protection trial has recently reported findings and shows a benefit of ezetimibe/simvastatin over simvastatin alone. AIM-HIGH (Atherothrombosis Intervention in Metabolic syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes), a trial of statin/niacin, has been prematurely halted for futility. Finally, combining a statin with both niacin and ezetimibe shows significant enhancement of the therapeutic effect on lipid profiles.

SUMMARY:

Current evidence continues to support initiation of a potent statin with titration to achieve targets. Combinations may be useful in individuals unable to reach desired lipid levels on maximal tolerated doses of statins.

PMID:
21832894
DOI:
10.1097/HCO.0b013e3283499ef1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center